Kumar, Anita
Sha, Fushen http://orcid.org/0000-0003-3262-323X
Toure, Ahmed
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Ni, Andy
Batlevi, Connie L.
Palomba, Maria Lia M.
Portlock, Carol
Straus, David J.
Noy, Ariela
Horwitz, Steven M.
Moskowitz, Alison
Hamlin, Paul
Moskowitz, Craig H.
Matasar, Matthew J.
Zelenetz, Andrew D.
Younes, Anas http://orcid.org/0000-0002-0001-4133
Article History
Received: 3 January 2019
Revised: 27 February 2019
Accepted: 3 April 2019
First Online: 20 May 2019
Conflict of interest
: A.K.: research funding from Abbvie Pharmaceuticals, Adaptive Biotechnologies, Celgene, Pharmacyclics, Seattle Genetics; advisory board member for Celgene (April 2016). F.S.: none. A.T.: none. A.D.: consultancy at Novartis, Weill-Cornell Hospital, Celgene, Seattle Genetics, Guidepoint Global Advisors, Pharmacyclics, Oncology Specialty Group, Roche, Peerview Institute, Physicians’ Education Resource, Corvus Pharmaceuticals. A.N.: none. C.L.B.: advisory for GLG, Defined Health; research funding from Novartis, Janssen, Bristol–Myers Squib, Epizyme, MedImmune; honoraria from Dava Oncology. M.L.M.P.: honoraria from Merck, Celgene and Pharmacyclics. C.P.: none. D.J.S.: consultancy at InPractice Elselvier, Seattle Genetics, Onco tracker (2016), Millenium (Takeda), DAVA (2016 and 2017), JUNO (2017), Bayer (2017); speaker’s bureau at ROCH China (2016), Medical Crossfire (2018). A.N.: research funding from Pharmacyclics, NIH, Raphael Pharma; consulting for: Janssen, Pharmacyclics, Medscape, Targeted Oncology. S.M.H.: consultancy at ADCT therapeutics, Aileron, Corvus, Forty-Seven, Innate Pharma, Kyowa-Hakka-Kirin, Millenium/Takeda, Mundipharma, Portola, Seattle Genetics; research funding from ADCT therapeutics, Aileron,Celgene, Forty-Seven, Infinity/Verastem, Kyowa-Hakka-Kirin, Millenium/Takeda, Seattle Genetics, Trillium. A.M.: consultancy at Kyowa Hakko Kirin Pharma, Miragen Therapeutics, Takeda Pharmaceuticals, ADC therapeutics, Seattle Genetics, Cell Medica, Bristol–Myers Squibb, Erytech Pharma; research funding from Incyte, Seattle Genetics, BMS, and Merck. P.H.: consultancy at Portola Pharmaceutics, Celgene, Karyopharm, Juno Therapeutics; research funding from Portola, Molecular Templates, Incyte, J&J Pharmaceuticals. C.H.M.: research funding from Merck, Seattle Genetics, BMS, ADC therapeutics Scientific Advisory Board: Novartis, Seattle Genetics, Takeda, Merck, BMS, Genentech, Astra Zeneca. M.J.M.: research funding from Genentech, Roche, GSK, Spectrum, Pharmacyclics, Seattle Genetics, Janssen; honoraria from Genentech, Roche, Spectrum, Janssen, Seattle Genetics, Rocket. A.D.Z.: consultancy at Genentech/Roche, Gilead, Celgene, Janssen, Amgen, Novartis, Adaptive Biotechnology; research funding MEI Pharma, MorphoSys, Sandoz, Celgene, Roche, Gilead; Board of Directors (DMC Chair) Beigene. A.Y.: research funding from Janssen, Novartis, Curis, Roche, BMS; honoraria or consulting fees from Bayer, Roche, BMS, Celgene, Incyte, Janssen, Curis, Takeda Millenium, Genentect, Merck, Xynomics, Bio-Path, and Epizyme.